On March 26, 2026, a complaint was filed against the Company and one of its current officer, alleging that throughout the Class Period, Defendants misrepresented and failed to disclose that: (1) Defendant Soon-Shion materially overstated Anktiva’s capabilities; and (2) as a result, Defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
